Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Testosterone and Weight Loss

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Austin Health
Information provided by (Responsible Party):
Mathis Grossmann, Austin Health Identifier:
First received: June 8, 2012
Last updated: February 8, 2014
Last verified: February 2014

The investigators hypothesise that testosterone therapy will synergize with dietary intervention to achieve weight loss. Obese men will receive diet, and be randomised to either testosterone therapy or placebo. Primary outcomes will be weight and body composition.

Condition Intervention Phase
Obesity in Men
Drug: Testosterone
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Testosterone and Diet on Weight

Resource links provided by NLM:

Further study details as provided by Austin Health:

Primary Outcome Measures:
  • weight [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: May 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: testosterone
against placebo
Drug: Testosterone
TU im
Placebo Comparator: placebo Drug: placebo
placebo im


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BMI >30

Exclusion Criteria:

  • contraindications to testosterone therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01616732

Contact: Mathis Grossmann

Australia, Victoria
Austin Health Recruiting
Heidelberg, Victoria, Australia, 3084
Principal Investigator: Mathis Grossmann         
Sponsors and Collaborators
Austin Health
  More Information

No publications provided

Responsible Party: Mathis Grossmann, Associate Professor, Austin Health Identifier: NCT01616732     History of Changes
Other Study ID Numbers: 04495
Study First Received: June 8, 2012
Last Updated: February 8, 2014
Health Authority: Australia: Human Research Ethics Committee

Additional relevant MeSH terms:
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 27, 2014